Jefferies maintained a Buy rating on Alnylam Pharmaceuticals (NASDAQ: ALNY), and cut the price target to $119.00 (from $122.00), following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE